American Association for Cancer Research
Browse
ccr-21-3231_supplementary_figure_2_supp2.docx (465.05 kB)

Supplementary Figure from Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response

Download (465.05 kB)
journal contribution
posted on 2023-03-31, 23:47 authored by Qing Zhou, Simon P. Gampenrieder, Sophie Frantal, Gabriel Rinnerthaler, Christian F. Singer, Daniel Egle, Georg Pfeiler, Rupert Bartsch, Viktor Wette, Angelika Pichler, Edgar Petru, Peter C. Dubsky, Zsuzsanna Bago-Horvath, Christian Fesl, Margaretha Rudas, Anders Ståhlberg, Ricarda Graf, Sabrina Weber, Nadia Dandachi, Martin Filipits, Michael Gnant, Marija Balic, Ellen Heitzer
Supplementary Figure from Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response

Funding

Austrian National Bank

Swedish Cancer Society

Swedish Research Council

ALF-agreement

History

ARTICLE ABSTRACT

Accurate response assessment during neoadjuvant systemic treatment (NST) poses a clinical challenge. Therefore, a minimally invasive assessment of tumor response based on cell-free circulating tumor DNA (ctDNA) may be beneficial to guide treatment decisions. We profiled 93 genes in tissue from 193 patients with early breast cancer. Patient-specific assays were designed for 145 patients to track ctDNA during NST in plasma. ctDNA presence and levels were correlated with complete pathological response (pCR) and residual cancer burden (RCB) as well as clinicopathologic characteristics of the tumor to identify potential proxies for ctDNA release. At baseline, ctDNA could be detected in 63/145 (43.4%) patients and persisted in 25/63 (39.7%) patients at mid-therapy (MT) and 15/63 (23.8%) patients at the end of treatment. ctDNA detection at MT was significantly associated with higher RCB (OR = 0.062; 95% CI, 0.01–0.48; P = 0.0077). Of 31 patients with detectable ctDNA at MT, 30 patients (96.8%) were nonresponders (RCB II, n = 8; RCB III, n = 22) and only one patient responded to the treatment (RCB I). Considering all 145 patients with baseline (BL) plasma, none of the patients with RCB 0 and only 6.7% of patients with RCB I had ctDNA detectable at MT, whereas 30.6% and 29.6% of patients with RCB II/III, respectively, had a positive ctDNA result. Overall, our results demonstrate that the detection and persistence of ctDNA at MT may have the potential to negatively predict response to neoadjuvant treatment and identify patients who will not achieve pCR or be classified with RCB II/III.

Usage metrics

    Clinical Cancer Research

    Categories

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC